Comparative evaluation of three commercial systems for detection of High-Risk Human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with Biopsy Results

Journal of Clinical Microbiology

Volumn 52, Issue 10, 2014, Pages 3763-3768

  Binnicker, M J ^a   Pritt, B S ^a   Duresko, B J ^a   Espy, M J ^a   Grys, T E ^a   Zarka, M A ^a   Kerr, S E ^a   Henry, M R ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; BIOPSY; CANCER CYTODIAGNOSIS; CANCER GRADING; CLINICAL EVALUATION; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; GYNECOLOGICAL EXAMINATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PAPANICOLAOU TEST; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL BIOPSY; VIRUS DETECTION; CLASSIFICATION; COMPARATIVE STUDY; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA; VIROLOGY;

BIOPSY; CERVIX UTERI; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINA;

EID: 84907164461     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01928-14     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention, Workowski KA, Berman SM. 2006. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recommend. Rep. 55(RR-11):1-94.
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048-1056. http://dx.doi.org/10.1016/S1470-2045(10)70230-8.
3. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 137:516-542. http://dx.doi.org/10.1309/AJCPTGD94EVRSJCG.
4. Priebe AM. 2013. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin. Obstet. Gynecol. 56:44-50. http://dx.doi.org/10.1097/GRF.0b013e3182836b6a.
5. Moyer VA, U.S. Preventive Services Task Force. 2012. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 156:880-891, W312. http://dx.doi.org/10.7326/0003-4819-156-12-201206190-00424.
6. Augustus P, Gabbur N. 2014. The importance of human papillomavirus 16/18 genotype risk stratification in atypical squamous cells of undetermined significance in an inner-city urban hospital. Obstet. Gynecol. 123(Suppl. 1): 87S. http://dx.doi.org/10.1097/01.AOG.0000447417.71070.10.
7. Wright TC, Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+cytology-negative results. Am. J. Clin. Pathol. 136:578-586. http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ.
8. Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197:346-355. http://dx.doi.org/10.1016/j.ajog.2007.07.047.
9. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur DC, Members of LAST Project Work Groups. 2012. The lower anogenital squamous terminology standardization project for HPVassociated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J. Low. Genit. Tract Dis. 16:205-242. http://dx.doi.org/10.1097/LGT.0b013e31825c31dd.
10. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. 2012. Comparison of the Hybrid Capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in Preserv-Cyt medium. J. Clin. Microbiol. 50:25-29. http://dx.doi.org/10.1128/JCM.05400-11.
11. Pyne MT, Law C, Hillyard DR, Schlaberg R. 2014. Testing and genotyping of high-risk human papillomavirus by the cobas HPV test and the Hybrid Capture 2 high-risk HPV DNA test using cervical and vaginal samples. J. Clin. Microbiol. 52:1720-1723. http://dx.doi.org/10.1128/JCM.03308-13.
12. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, Ruiz F, Smith JS. 2011. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: The FASE study. Int. J. Cancer 129:691-701. http://dx.doi.org/10.1002/ijc.25726.
13. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, Sideri M, Khiri H, Ravet S, Boyle S, Aldrich C, Halfon P. 2012. Analytical comparison of the cobas HPV test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14:65-70. http://dx.doi.org/10.1016/j.jmoldx.2011.09.005.
14. Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlee F. 2012. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J. Clin. Microbiol. 50:1240-1244. http://dx.doi.org/10.1128/JCM.06656-11.
15. Cui M, Chan N, Liu M, Thai K, Malaczynska J, Singh I, Zhang D, Ye F. 2014. Clinical performance of Roche cobas 4800 HPV test. J. Clin. Microbiol. 52:2210-2211. http://dx.doi.org/10.1128/JCM.00883-14.
16. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J. 2013. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. Int. J. Cancer 132:101-108. http://dx.doi.org/10.1002/ijc.27636.
17. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J. 2012. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: The Predictors 2 study. J. Clin. Microbiol. 50:1867-1873. http://dx.doi.org/10.1128/JCM.00181-12.
18. Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K. 2014. Evaluation of commercial HPV assays in the context of posttreatment follow-up: Scottish Test of Cure Study (STOCS-H). J. Clin. Pathol. 67:458-463. http://dx.doi.org/10.1136/jclinpath-2013-202014.
19. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Steinau M, Markowitz LE. 2012. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J. Infect. Dis. 206:1878-1886. http://dx.doi.org/10.1093/infdis/jis627.
20. Sauter JL, Mount SL, St John TL, Wojewoda CM, Bryant RJ, Leiman G. 2014. Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care? Acta Cytol. 58:162-166. http://dx.doi.org/10.1159/000358246.